Andrew I. Koven - Jun 22, 2023 Form 4 Insider Report for Kala Pharmaceuticals, Inc. (KALA)

Role
Director
Signature
/s/ Mary Reumuth, Attorney-in-Fact
Stock symbol
KALA
Transactions as of
Jun 22, 2023
Transactions value $
$0
Form type
4
Date filed
6/23/2023, 08:00 PM
Previous filing
Jun 2, 2023
Next filing
Jul 28, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALA Common Stock Award $0 +7.52K +230.73% $0.00 10.8K Jun 22, 2023 Direct F1, F2
transaction KALA Common Stock Award $0 +1.4K +13% $0.00 12.2K Jun 22, 2023 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALA Stock Option (right to buy) Award $0 +10K $0.00 10K Jun 22, 2023 Common Stock 10K $14.56 Direct F5
transaction KALA Stock Option (right to buy) Award $0 +3.15K $0.00 3.15K Jun 22, 2023 Common Stock 3.15K $14.56 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 1/3 of the shares underlying the RSUs on June 22, 2024, as to 1/3 of the shares underlying the RSUs on June 22, 2025 and as to the final 1/3 of shares underlying the RSUs on June 22, 2026.
F2 Includes 10,772 unvested RSUs.
F3 Grant of RSUs under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 22, 2024 or (ii) the date of the first annual meeting following June 22, 2023.
F4 Includes 12,172 unvested RSUs.
F5 This option was granted on June 22, 2023 and vests over four years beginning on the vesting commencement date of June 22, 2023, with 25% of the shares underlying the option vesting on June 22, 2024, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter.
F6 This option was granted on June 22, 2023 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 22, 2024 or (ii) the date of the first annual meeting following June 22, 2023.